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Abstract
Thrombotic microangiopathy (TMA) syndromes can be secondary to a multitude of different diseases. Most can be identi-
fied with a systematic approach and, when excluded, TMA is generally attributed to a dysregulation in the activity of the 
complement alternative pathways—atypical hemolytic uremic syndrome (aHUS). We present a challenging case of a 19-year-
old woman who presented with thrombotic microangiopathy, which was found to be caused by methylmalonic acidemia 
and homocystinuria, a rare vitamin B12 metabolism deficiency. To our knowledge, this is the first time that an adult-onset 
methylmalonic acidemia and homocystinuria presents as TMA preceding CNS involvement.
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Introduction
Thrombotic microangiopathy (TMA) syndromes are a rare 
and potentially fatal group of diseases. While their etiologies 
can be surprisingly diverse, TMAs share a similar patho-
physiological pathway of small vessel narrowing and occlu-
sions caused by microthrombi, resulting in the typical clini-
cal picture of microangiopathic hemolytic anemia (MAHA), 
consumptive thrombocytopenia, and ischemic lesions of 
small-vessel-rich organs, such as the brain and the kidney. 
Reflecting the common final phenotype of endothelial cell 
injury, renal morphology features are also fairly alike among 
the many causes of TMA [1, 2].
Despite these homogenous clinical features, TMAs’ treat-
ment differs substantially depending on its root cause. This 
implies diagnostic tools to distinguish the many different 
causes that have so far been described—including second-
ary to autoimmune diseases, malignant hypertension, HIV, 
drugs, shiga toxin-producing Escherichia coli infection, 
or the more recently recognized ‘atypical HUS (aHUS)’, a 
TMA driven by inherited complement alternative pathway 
dysregulation [2].
The authors report a case of a 19-year-old white female 
patient displaying combined methylmalonic acidemia and 
homocystinuria, a defect in cobalamin metabolism, which 
manifested as a thrombotic microangiopathy.
Case report
A 19-year-old woman, who had been irregularly followed 
by a pediatric psychiatrist for the previous 3 years due to 
depression and learning difficulties, was observed by her 
general practitioner complaining of menorrhagia. She had 
a normocytic anemia of 10 g/L and a normal platelet count 
of 270 × 109/L. She was also found to be hypertensive at 
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that time, and was started on a beta-blocker and an oral 
contraceptive pill. A few weeks later, she presented to the 
emergency department, complaining of nausea, fatigue, 
abdominal pain, and generally feeling unwell. At admis-
sion, she had a macrocytic anemia (5.4 × 10 g/L), plate-
lets 82 × 109/L, LDH 901 U/L (reference value 250–450), 
haptoglobin < 0.07  g/L (reference value 0.8–2.0), pres-
ence of schizocytes, and a serum creatinine of 2.85 mg/dL 
(252 µmol/L).
Microangiopathic hemolytic anemia along with acute kid-
ney injury due to TMA was diagnosed and the patient was 
started on plasma exchange (PLEX), while secondary causes 
of TMA were being excluded. She had normal ADAMTS13 
activity, with no auto-antibodies against ADAMTS13; anti-
nuclear antibodies, anti-dsDNA, anti-Scl70, phospholipid 
syndrome antibodies, and Coombs test, search for human 
immunodeficiency; hepatitis B and hepatitis C virus were 
all negative; C3 and C4 were within the normal range; Shiga 
toxin search was negative; and pregnancy was also excluded.
Despite five consecutive days of PLEX, the patient’s 
clinical parameters remained unstable, requiring several 
blood transfusions and urgent dialysis was started. As our 
investigation for secondary causes of TMA was negative, 
the patient was assumed to have aHUS refractory to PLEX 
and was started on eculizumab. Despite eculizumab therapy 
for 3 weeks, with efficient complement blockade (measured 
by CH50), hemolysis parameters remained high, requiring 
frequent blood transfusions along with undetectable hapto-
globin levels. It was at this point that the clinical features 
changed, as the patient started showing neuropsychiatric 
symptoms (compulsive behavior and visual hallucinations, 
ataxic gait, drooling, and extreme somnolence), along with 
no improvement in renal function.
At this point, rare secondary causes were considered—
the neurologic involvement prompted us to evaluate serum 
total homocysteine levels, that were found to be extremely 
elevated (434 μmol/L—reference value < 20), establishing 
the diagnosis of a vitamin  B12 metabolism error, confirmed 
by elevated serum methylmalonic acid (9.3 µmol/L—refer-
ence value < 0.27; gas chromatography–mass spectrometry) 
and low methionine (6 μmol/L—reference value 11–37; gas 
chromatography–ion detector)—the methylmalonic aci-
demia and homocystinuria diagnosis would later be con-
firmed by molecular studies showing compound heterozy-
gous mutations in the MMACHC gene (mRNA accession 
number NM_015506.2)—c.271dupA (p.Arg91Lysfs*14) 
and c.565C>A (p.Arg189Ser); initial metabolic serum and 
plasma evaluation were all performed in samples collected 
before PLEX was initiated. Transthoracic echocardiogram 
showed no signs of pulmonary hypertension.
Therapy with intramuscular hydroxocobalamin (5 mg, 
three times a week), folinic acid (10 mg/day), and levo-
carnitine (3 g/day) was started, with rapid and significant 
neurological improvement after just a few days of therapy, 
as well as progressive resolution of hemolytic parameters. 
Renal biopsy could then be safely performed and a severe 
TMA glomerular and vascular lesions were documented 
(Fig. 1). Meanwhile, the negative search for mutations in 
the genes encoding the complement regulating proteins by 
next generation sequencing and multiplex ligation-depend-
ent probe amplification of CFH, CFHR1, CFHR3, CFHR4, 
CFI, CFB, C3, THBD, and DGKE (as previously described 
[3]) allowed for a cautious eculizumab suspension; we saw 
no relapse in hemolysis parameters thereafter. After almost 
12 months of effective targeted therapy, despite full neu-
rological and hematological recovery, the patient remains 
dialysis dependent, and is now being considered for renal 
transplantation.
Discussion
This is a case of a severe form of TMA, found to be unre-
sponsive to PLEX and with no obvious secondary causes, 
leading to the diagnosis of aHUS and eculizumab therapy. 
After 3 weeks of unsuccessful treatment with the comple-
ment blocking drug and the development of neuropsychiatric 
symptoms, methylmalonic acidemia associated with homo-
cystinuria was considered.
Fig. 1  Light microscopy, Jones silver stain (×  20)—2 ischemic glo-
meruli (full arrows), both with thickening of the glomerular basement 
membrane; 2 vessels displaying obliteration of the arteriolar lumen 
due to organized non-recent thrombus (dashed arrows)
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Vitamin  B12 (also known as cobalamin [Cbl]) has a 
complex metabolism, as it functions as a cofactor for two 
enzymes: (1) methyltetrahydrofolate methyltransferase, 
which catalyzes the conversion of homocysteine to methio-
nine in cytoplasm and (2) methylmalonyl-CoA mutase, 
which catalyzes the conversion of methylmalonyl-CoA to 
succinyl-CoA in mitochondria [4]. There can be several 
errors in Cbl’s metabolism, which result in the combi-
nation of accumulation of homocysteine and/or methyl-
malonic acid (MMA), and a deficiency in methionine. 
While rare (with an estimated incidence of 1/85,000 in 
our country [5]), combined methylmalonic acidemia and 
homocystinuria (also termed CblC type), is the most fre-
quent of these disorders, and is caused by mutations in the 
MMACHC gene [6, 7].
The pathophysiology of CblC is not fully understood, but 
it is likely the result of the synergistic effect of the toxicity of 
homocysteine and methylmalonic acid and the deficiency in 
methionine. Even less clear, is how it results in TMA—some 
argue that the toxic homocysteine levels cause endothelial 
damage, which in turn produces complement activation [8, 
9].
Despite exceedingly variable clinical phenotypes, the 
typical presentation occurs in newborns, manifestations 
being predominantly neurological. Late-onset manifesta-
tions in childhood and adulthood are less frequent, and while 
neurological manifestations continue to be more frequent, 
thromboembolic events are also relatively common—TMA 
being one of them [10]. However, the report of MMACHC 
mutations has allowed for genotype–phenotype correla-
tions regarding age of onset. The association of two del-
eterious mutations found in our patient has been previously 
described, c.271dupA being one of the most common muta-
tion in Portuguese patients [11, 12]. All patients homozy-
gous for the c.271dupA mutation have presented with early 
onset disease. Conversely, the individuals with compound 
heterozygous mutations for the c.271dupA mutation and a 
missense mutation, as our patient, have been correlated with 
later onset of disease, presenting as late as 10–20 years of 
age [11]. It is possible that transcripts containing the mis-
sense allele are translated into proteins with residual func-
tion [6].
Clinical suspicion is fundamental, as it will lead to tar-
geted biochemical testing. In our institution, serum homo-
cysteine is readily available, and allowed for a presumptive 
diagnosis and therapy start. The search for urine organic 
acids, serum MMA, and plasma amino acids should also be 
done. There are an increasing number of reports, suggesting 
that serum homocysteine and MMA should be requested for 
every patient presenting with TMA [13]. Of note, vitamin 
 B12 levels are normal and will not help in diagnosis. The 
screening of mutations in MMACHC will confirm the 
diagnosis.
The treatment goal is to normalize serum methionine 
and to lower homocysteine and MMA as soon as possi-
ble, which can be achieved through the administration of 
hydroxocobalamin and betaine; folinic acid and levocarni-
tine might also be beneficial, but their efficacy is not estab-
lished. Of note, hydroxocobalamin administration needs to 
be parental (intramuscular, subcutaneous, or intravenous), 
as neither oral hydroxocobalamin nor parenteral cyano-
cobalamin seem to be effective. Serum homocysteine is 
useful for monitoring metabolic control of the disease and 
hydroxocobalamin dose management [10].
In our case, the adult-onset TMA manifestation meant 
that we were ill-prepared for this diagnosis: by the time it 
was attained and therapy started, the patient had already 
severely damaged kidney function, and despite a full 
recovery of neurological and hemolytic parameters, the 
patient remains dialysis dependent—Fig.  2. In recent 
years, TMAs have been recognized to represent the inter-
action of a predisposition background and a triggering 
event—typically infections or drugs. Compound mutations 
for CblC help explain the silent course of disease until the 
patient was 19 years. In our view, beta-blocker and an oral 
contraceptive pill recent introduction probably represent 
the trigger for full-blown CblC manifestations. In addi-
tion, oral contraceptives are known to potentially cause 
disturbed  B12 absorption [14]. Theoretically, this could 
further enhance disease manifestations. Learning difficul-
ties had been identified during our patient’s childhood, 
which could be interpreted as subtle ClbC manifestations; 
however, we saw no improvement during follow-up, and 
despite no formal cognitive or neuro-psychological evalu-
ation, we do not think that the patient’s learning difficulties 
are attributable to CblC.
Eculizumab-resistant TMA due to CblC has been previ-
ously reported [15], albeit without neurological symptoms. 
To our knowledge, this is the first time that an adult-onset 
methylmalonic acidemia and homocystinuria presents as 
TMA preceding CNS involvement.
In summary, TMAs are severe life-threatening syn-
dromes, whose secondary causes should be promptly and 
aggressively investigated, especially in the cases where 
there is no response to anti-C5 therapy. Methylmalonic 
acidemia with homocystinuria is a rare disease, usually 
diagnosed in infancy, manifestations being predominantly 
neurological. Its manifestation as TMA is unusual, and can 
easily be ruled out by measuring serum homocysteine. The 
outcome is usually dismal, but aggressive B12 administra-
tion for life can control the disease.
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Fig. 2  Evolution of biochemical features of hemolysis throughout the major clinical events
